Theraclion to Present at the 18th Annual Rodman & Renshaw Global Investment Conference

Regulatory News:

THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that it will be presenting at the 18^th Annual Rodman & Renshaw Global Investment Conference, being held on September 11-13, 2016, at The Lotte New York Palace Hotel in New York City.

David Caumartin, Theraclion’s CEO, will provide an overview of the Company’s Echopulse® system for the treatment of breast fibroadenomas and thyroid nodules, as well as its strategy to expand its global footprint. The management team will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the link (www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Details for the presentation are as follows:

• Date: Monday, September 12, 2016
• Time: 5:30 p.m. EDT
• Room: Holmes I

The presentation will also be webcast live. To access the webcast, please visit the events page of the Company’s website (http://www.theraclion.com/category/news/events/). The webcast replay will remain available for 90 days following the live presentation.

About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

View source version on businesswire.com: http://www.businesswire.com/news/home/20160907005989/en/